Shaomeng Wang

USPTO Granted Patents = 77 (Patent Applications = 36)

CIPO Patents = 3 (Patent Applications = 13)

EPO Patents = 27 (Patent Applications = 43)

Average Co-Inventor Count = 4.5

ph-index = 11

Forward Citations = 449(Granted Patents)

Inventors with similar research interests:

Location History:

McLean, VA (US) (2000)
McLeane, VA (US) (1999 - 2001)
Rockville, MD (US) (2004 - 2008)
Saline, MI (US) (2004 - 2017)
Superior Township, MI (US) (2017 - 2024)

Company Filing History:

67 out of 3,370

University of Michigan

patents

9 out of 484

Georgetown University

patents

3 out of 30

Ascentage Pharma (suzhou) Co., Ltd.

patents

4. 3 out of 20

Ascentage Pharma Group Corp Limited

Ascenta Licensing Corporation

patent

7. 1 out of 31

Adherex Technologies, Inc.

patents

8. 1 out of 2

Jiangsu Ascentage Biomed Development Inc.

where one patent can have more than one assignee

Years Active: 1999-2025

Loading Chart...

Areas of Expertise:

Mcl-1 Inhibitors

EED Inhibitors

DCN1 Inhibitors

LSD-1 Inhibitors

Bcl-2 Inhibitors

BET Bromodomain Inhibitors

MDM2 Protein Degraders

ALK Inhibitors

Covalent Inhibitors

Peptidomimetic Inhibitors

Anaplastic Lymphoma Kinase

Small Molecule Therapeutics

77 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12319703 - Macrocyclic fused pyrazoles as Mcl-1 inhibitors (2025-06-03),

2. 12145944 - Imidazopyrimidines as EED inhibitors and the use thereof (2024-11-19),

3. 12012467 - Small molecule DCN1 inhibitors and therapeutic methods using the same (2024-06-18),

4. 11944614 - Imidazo[4,5-c]pyridine compounds as LSD-1 inhibitors (2024-04-02),

5. 11718613 - N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitors (2023-08-08),

6. 11691989 - Macrocyclic indoles as Mcl-1 inhibitors (2023-07-04),

7. 11548899 - Fused 1,4-oxazepines and related analogs as BET bromodomain inhibitors (2023-01-10),

8. 11498928 - Macrocyclic spiroethers as Mcl-1 inhibitors (2022-11-15),

9. 11466028 - Fused 1,4-oxazepines as BET protein degraders (2022-10-11),

10. 11267822 - BET bromodomain protein degraders with cleavable linkers (2022-03-08),

11. 11192898 - MDM2 protein degraders (2021-12-07),

12. 11168082 - Pyrrolo[2,3-C]pyridines and related analogs as LSD-1 inhibitors (2021-11-09),

13. 11110090 - Aminopyrimidines as ALK inhibitors (2021-09-07),

14. 11046709 - Fused 1,4-diazepines as BET bromodomain inhibitors (2021-06-29),

15. 11046703 - Small molecule MDM2 protein degraders (2021-06-29),

Title: The Innovative Journey of Shaomeng Wang

Introduction: Shaomeng Wang, a pioneering inventor based in Saline, MI (US), has made significant contributions to the field of innovation through his groundbreaking work in various patents and inventions.

Latest Patents: Shaomeng Wang holds several patents in the areas of pharmaceuticals and biotechnology, with his most recent patent focusing on a novel drug delivery system for targeted cancer therapy.

Career Highlights: Wang's illustrious career includes serving as a lead researcher at a prominent pharmaceutical company, where he spearheaded the development of cutting-edge treatments for complex diseases. His innovative approach to drug discovery has led to the successful commercialization of several life-saving medications.

Collaborations: Throughout his career, Shaomeng Wang has collaborated with top researchers, scientists, and medical professionals from renowned institutions and universities worldwide. His collaborative efforts have resulted in the publication of numerous research papers and the advancement of scientific knowledge in the field.

Conclusion: Shaomeng Wang's dedication to innovation and his relentless pursuit of excellence have established him as a trailblazer in the world of inventors. His remarkable contributions continue to inspire future generations of inventors and researchers to push the boundaries of what is possible in the realm of science and technology.

This text is generated by artificial intelligence and may not be accurate.